Chugai Seiyaku Kabushiki Kaisha;Hoffmann-La Roche Inc.
发明人:
Xiaoping Zhang,Kimio Terao,Olivier Alfred Harari
申请号：
US14062026
公开号：
US20140056885A1
申请日:
2013.10.24
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
